Later course accelerated hyperfractionated radiotherapy combine chemotherapy for stage Ⅲ and Ⅳ a nasopharyngeal carcinoma
- VernacularTitle:Ⅲ期、Ⅳa期鼻咽癌后程加速超分割放疗联合化疗的临床研究
- Author:
Qiaoying HU
;
Peng LIU
- Publication Type:Journal Article
- Keywords:
Later course accelerated hyperfractionated radiotherapy combine chemotherapy;
Nasopharyngeal carcinoma
- From:
Cancer Research and Clinic
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluated the treatment results of late course accelerated fractionation radiotherapy for Stage Ⅲ and Ⅳa nasopharyngeal carcinoma. Methods 100 patients with stage Ⅲ and Ⅳa nasopharyngeal carcinoma were randomized into two groups. The late course accelerated hyperfractionated radiotherapy combine chemotherapy group(LCAF+CT group) received the induction chemotherapy for two cycles, followed by conventional fractionation radiotherapy to a dose 40 Gy, than changed into accelerated hyperfractionated radiotherapy to a total dose of 70 Gy, and use two cycles adjuvant chemotherapy, The conventional fractionation radiotherapy combine chemotherapy group(CF+CT group) received the chemotherapy that it similar to the LCAF+CT group, and use the conventional fractionation radiotherapy to a total dose of 70 Gy. Results The 3- and 5-year overall survival rate were 70.0% and 62.0% respectively in LCAF+CT group and 58.0 % and 46.0 % respectively in CF+CT group, had the significant difference (P 0.05). There were the cranial nerves complications in two patients of LCAF+CT group. Conclusions The results from this study show that the 3- and 5-year overall survival rate, the 3- and 5-year disease free survival rate and the 3- and 5-year local-regional free survival rate in LCAF+CT group was significant better than in CF+CT group, but the radiation-induced damage to the cranial nerves was improved in LCAF+CT group.
